首页> 外文期刊>Molecular and Cellular Biology >SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene.
【24h】

SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene.

机译:SOX9是pro alpha1(II)胶原基因的软骨细胞特异性增强子的有效激活剂。

获取原文
           

摘要

The identification of mutations in the SRY-related SOX9 gene in patients with campomelic dysplasia, a severe skeletal malformation syndrome, and the abundant expression of Sox9 in mouse chondroprogenitor cells and fully differentiated chondrocytes during embryonic development have suggested the hypothesis that SOX9 might play a role in chondrogenesis. Our previous experiments with the gene (Col2a1) for collagen II, an early and abundant marker of chondrocyte differentiation, identified a minimal DNA element in intron 1 which directs chondrocyte-specific expression in transgenic mice. This element is also a strong chondrocyte-specific enhancer in transient transfection experiments. We show here that Col2a1 expression is closely correlated with high levels of SOX9 RNA and protein in chondrocytes. Our experiments indicate that the minimal Col2a1 enhancer is a direct target for Sox9. Indeed, SOX9 binds to a sequence of the minimal Col2a1 enhancer that is essential for activity in chondrocytes, and SOX9 acts as a potent activator of this enhancer in cotransfection experiments in nonchondrocytic cells. Mutations in the enhancer that prevent binding of SOX9 abolish enhancer activity in chondrocytes and suppress enhancer activation by SOX9 in nonchondrocytic cells. Other SOX family members are ineffective. Expression of a truncated SOX9 protein lacking the transactivation domain but retaining DNA-binding activity interferes with enhancer activation by full-length SOX9 in fibroblasts and inhibits enhancer activity in chondrocytes. Our results strongly suggest a model whereby SOX9 is involved in the control of the cell-specific activation of COL2A1 in chondrocytes, an essential component of the differentiation program of these cells. We speculate that in campomelic dysplasia a decrease in SOX9 activity would inhibit production of collagen II, and eventually other cartilage matrix proteins, leading to major skeletal anomalies.
机译:轮状发育不全,严重骨骼畸形综合征以及小鼠软骨生成细胞和完全分化的软骨细胞中Sox9大量表达的SRY相关SOX9基因突变的鉴定表明,SOX9可能起一定作用在软骨形成中。我们以前用胶原蛋白II(软骨细胞分化的早期和丰富标记)基因(Col2a1)进行的实验确定了内含子1中最小的DNA元件,该元件指导着转基因小鼠中软骨细胞的特异性表达。在瞬时转染实验中,该元素也是软骨细胞特异性增强剂。我们在这里显示,Col2a1表达与软骨细胞中高水平的SOX9 RNA和蛋白质密切相关。我们的实验表明,最小的Col2a1增强子是Sox9的直接靶标。实际上,SOX9结合了最小的Col2a1增强子序列,该序列是软骨细胞活性所必需的,并且SOX9在非软骨细胞的共转染实验中充当了该增强子的有效激活剂。阻止SOX9结合的增强子突变消除了软骨细胞中的增强子活性,并抑制了非软骨细胞中SOX9的增强子激活。其他SOX家族成员无效。缺少反式激活结构域但保留DNA结合活性的截短的SOX9蛋白的表达会干扰成纤维细胞中全长SOX9的增强子激活,并抑制软骨细胞中的增强子活性。我们的结果有力地提出了一个模型,其中SOX9参与了软骨细胞中细胞特异性COL2A1活化的控制,而软骨细胞是这些细胞分化程序的重要组成部分。我们推测在坎波型不典型增生中,SOX9活性的降低会抑制胶原II的产生,并最终抑制其他软骨基质蛋白的产生,从而导致严重的骨骼异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号